Neuraminidase Inhibitor Susceptibility Network position statement: Antiviral resistance in influenza A/H5N1 viruses

Frederick Hayden*, Alexander Klimov, Masato Tashiro, Alan Hay, Arnold Monto, Jennifer McKimm-Breschkin, Catherine Macken, Alan Hampson, Robert G. Webster, Michèle Amyard, Maria Zambon

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

47 Citations (Scopus)

Abstract

The emerging epidemic of H5N1 avian influenza virus with spillover into the human population in Asia has provoked intense concern globally about the potential of these particularly pathogenic viruses to evolve with the capacity for human-to-human transmission with a consequent pandemic. The availability of antiviral drugs with activity against influenza A viruses and the recognition of drug-resistant variants to these drugs prompted the following report by a select group of the global experts - members of the Neuraminidase Inhibitor Susceptibility Network - on the best use of the available drugs, both for prophylaxis and treatment. The editors of Antiviral Therapy are pleased to be able to provide this document in an expeditious manner.

Original languageEnglish
Pages (from-to)873-877
Number of pages5
JournalAntiviral Therapy
Volume10
Issue number8
Publication statusPublished - 2005

Fingerprint

Dive into the research topics of 'Neuraminidase Inhibitor Susceptibility Network position statement: Antiviral resistance in influenza A/H5N1 viruses'. Together they form a unique fingerprint.

Cite this